AbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up Humira's mantle

The reports of AbbVie’s demise have been greatly exaggerated. Gone are the worries of Humira competition and its monumental patent cliff. The “lack of a shiny object” in the pipeline is a ...